RTP Mobile Logo
Select Publications

Bishop MR et al. Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: Analysis of the phase III Belinda study. ASH 2021;Abstract LBA-6.

Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800. Abstract

Carlo-Stella C et al. Planned interim analysis of a phase 2 study of loncastuximab tesirine plus ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3). ASH 2021;Abstract 54.

Fowler NH et al. Umbralisib, a dual PI3K-delta/CK1-epsilon inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39(15):1609-18. Abstract

Goldman A et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol 2021;78(18):1800-13. Abstract

Hutchings M et al. Glofitamab (glofit) in combination with polatuzumab vedotin (pola): Phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). ASH 2021;Abstract 525.

Isaac KM et al. Leukemic variant of mantle cell lymphoma: Clinical presentation and management. Curr Oncol Rep 2021;23(9):102. Abstract

Jacobson C et al. Long-term (4- and 5-year) overall survival in ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large B-cell lymphoma (LBCL). ASH 2021;Abstract 1764.

Kahl BS et al. Long term follow up of the resort study (E4402): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. ASH 2021;Abstract 815.

Kalakonda N et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7(7):e511-22. Abstract

Kamdar M et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Results from the randomized phase 3 TRANSFORM study. ASH 2021;Abstract 91.

Kumar A et al. Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J Clin Oncol 2021;39(20):2257-65. Abstract

Kuruvilla J et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22(4):512-24. Abstract

Locke FL et al. Primary analysis of ZUMA‑7: A phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard‑of‑care therapy in patients with relapsed/refractory large B-cell lymphoma. ASH 2021;Abstract 2.

Matasar MJ et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(5):678-89. Abstract

Portell CA et al. Dose finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. Blood Adv 2021;[Online ahead of print]. Abstract

Salles G et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21(7):978-88. Abstract

Sehn LH et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155-65. Abstract

Straus DJ et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8(6):e410-21. Abstract

Tilly H et al. The POLARIX Study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma. ASH 2021;Abstract LBA-1.

Westin JR et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol 2021;96(10):1295-1312. Abstract